Pulmonary arterial hypertension
Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of:
- idiopathic pulmonary arterial hypertension
- heritable pulmonary arterial hypertension
- pulmonary arterial hypertension associated with connective tissue diseases
- pulmonary arterial hypertension associated with congenital heart disease
in adult patients with WHO functional Class II, III or IV symptoms.
Package - Contents - Shelf Life: Blister pack, PP/Al - 42 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, PP/Al - 84 tablets - 36 months from date of manufacture stored at or below 30°C